Global X Funds. Holdings as of May 31, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| GUARDANT HEALTH, INC.GH | 5.59% | $3.12M | 24,059 |
| ILLUMINA, INC.ILMN | 4.82% | $2.69M | 16,512 |
| NATERA, INC.NTRA | 4.15% | $2.32M | 10,370 |
| BIOMARIN PHARMACEUTICAL INC.BMRN | 4.09% | $2.28M | 39,792 |
| ARROWHEAD PHARMACEUTICALS, INC.ARWR | 4.07% | $2.27M | 29,150 |
| Legend Biotech CorpLEGN | 4.05% | $2.26M | 83,099 |
| Praxis Precision Medicines IncPRAX | 4.01% | $2.24M | 6,388 |
| Twist Bioscience CorpTWST | 3.97% | $2.21M | 33,087 |
| VERTEX PHARMACEUTICALS INCORPORATEDVRTX | 3.95% | $2.20M | 4,923 |
| CRISPR Therapeutics AG | 3.85% | $2.15M | 38,191 |
| Veracyte IncVCYT | 3.64% | $2.03M | 43,807 |
| Qiagen N.V. | 3.54% | $1.97M | 53,909 |
| BioNTech SEBNTX | 3.41% | $1.90M | 19,841 |
| BIO-TECHNE CORPORATIONTECH | 3.41% | $1.90M | 36,783 |
| MODERNA, INC.MRNA | 3.28% | $1.83M | 38,755 |
| 10X Genomics IncTXG | 3.23% | $1.80M | 63,665 |
| Beam Therapeutics IncBEAM | 3.09% | $1.72M | 52,306 |
| BNYREPOSRA | 3.05% | $1.70M | 1,700,474 |
| ASTRAZENECA PLC | 1.83% | $1.38M | 5,490 |
| ELI LILLY AND COMPANYLLY | 2.32% | $1.29M | 1,169 |
| Ultragenyx Pharmaceutical IncRARE | 2.25% | $1.26M | 52,426 |
| CARIS LIFE SCIENCES, INC.CAI | 2.03% | $1.13M | 67,748 |
| BillionToOne IncBLLN | 1.97% | $1.10M | 11,121 |
| GILEAD SCIENCES, INC.GILD | 1.95% | $1.09M | 8,107 |
| SAREPTA THERAPEUTICS, INC.SRPT | 1.80% | $1.00M | 56,133 |
| Uniqure NV | 1.59% | $889.79K | 31,188 |
| INTELLIA THERAPEUTICS, INC.NTLA | 1.59% | $888.30K | 63,134 |
| Stoke Therapeutics IncSTOK | 1.45% | $810.83K | 26,232 |
| GeneDx Holdings CorpWGS | 1.35% | $752.92K | 14,482 |
| DANAHER CORPORATIONDHR | 1.17% | $652.68K | 3,573 |
| BRISTOL-MYERS SQUIBB COMPANYBMY | 1.16% | $644.59K | 11,273 |
| Vir Biotechnology IncVIR | 1.11% | $619.15K | 64,900 |
| CAREDX, INC.CDNA | 1.05% | $587.27K | 25,735 |
| WAVE Life Sciences LtdWVE | 1.03% | $574.16K | 87,259 |
| Personalis IncPSNL | 0.79% | $438.62K | 38,475 |
| Maravai LifeSciences Holdings IncMRVI | 0.51% | $282.29K | 58,810 |
| BRUKER CORPORATIONBRKR | 0.43% | $238.86K | 4,056 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB | 0.40% | $225.64K | 151,435 |
| Benitec Biopharma IncBNTC | 0.38% | $212.13K | 18,350 |
| AGILENT TECHNOLOGIES, INC.A | 0.38% | $210.48K | 1,553 |
| FULGENT GENETICS, INC.FLGT | 0.36% | $200.08K | 11,030 |
| STANDARD BIOTOOLS INC.LAB | 0.35% | $196.40K | 170,786 |
| MYRIAD GENETICS, INC.MYGN | 0.35% | $194.38K | 48,961 |
| EDITAS MEDICINE, INC.EDIT | 0.34% | $189.35K | 54,725 |
| Prime Medicine, IncPRME | 0.34% | $188.54K | 53,111 |
| Regenxbio IncRGNX | 0.33% | $181.47K | 25,888 |
| ROCKET PHARMACEUTICALS, INC.RCKT | 0.32% | $176.86K | 57,609 |
| MESA LABORATORIES, INC.MLAB | 0.29% | $162.11K | 1,589 |
| Caribou Biosciences IncCRBU | 0.29% | $160.91K | 68,184 |
| QUEST DIAGNOSTICS INCORPORATEDDGX | 0.28% | $153.78K | 789 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.